Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma

Mutations in Fanconi Anemia or Homologous Recombination (FA/HR) genes can cause DNA repair defects and could therefore impact cancer treatment response and patient outcome. Their functional impact and clinical relevance in head and neck squamous cell carcinoma (HNSCC) is unknown. We therefore questioned whether functional FA/HR defects occurred in HNSCC and whether they are associated with FA/HR variants. We assayed a panel of 29 patient-derived HNSCC cell lines and found that a considerable fraction is hypersensitive to the crosslinker Mitomycin C and PARP inhibitors, a functional measure of FA/HR defects. DNA sequencing showed that these hypersensitivities are associated with the presence of bi-allelic rare germline and somatic FA/HR gene variants. We next questioned whether such variants are associated with prognosis and treatment response in HNSCC patients. DNA sequencing of 77 advanced stage HNSCC tumors revealed a 19% incidence of such variants. Importantly, these variants were associated with a poor prognosis (p = 0.027; HR = 2.6, 1.1–6.0) but favorable response to high cumulative cisplatin dose. We show how an integrated in vitro functional repair and genomic analysis can improve the prognostic value of genetic biomarkers. We conclude that repair defects are marked and frequent in HNSCC and are associated with clinical outcome.

[1]  A. Adeyemo,et al.  Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50 , 2017, Cancer.

[2]  M. Berger,et al.  The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform , 2017, JAMA oncology.

[3]  Trevor Hastie,et al.  REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. , 2016, American journal of human genetics.

[4]  S. Kaye,et al.  BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  A. Eisbruch,et al.  Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review , 2016, Head & neck.

[6]  Eric Talevich,et al.  CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..

[7]  Mechthild Krause,et al.  Radiation oncology in the era of precision medicine , 2016, Nature Reviews Cancer.

[8]  D. Aust,et al.  Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(−) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG , 2016, Clinical Cancer Research.

[9]  M. O’Connor,et al.  Targeting the DNA Damage Response in Cancer. , 2015, Molecular cell.

[10]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[11]  M. O’Connor,et al.  Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  S. Feller,et al.  Defects in the Fanconi Anemia Pathway and Chromatid Cohesion in Head and Neck Cancer. , 2015, Cancer research.

[13]  Peter Bouwman,et al.  REV7 counteracts DNA double-strand break resection and affects PARP inhibition , 2015, Nature.

[14]  R. Tollenaar,et al.  Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis , 2015, PloS one.

[15]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[16]  A. Sieuwerts,et al.  Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment , 2014, Clinical Cancer Research.

[17]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[18]  S. Rodenhuis,et al.  Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy , 2014, Breast Cancer Research.

[19]  C. Scully,et al.  Joint and Independent Effects of Alcohol Drinking and Tobacco Smoking on Oral Cancer: A Large Case-Control Study , 2013, PloS one.

[20]  J. Grandis,et al.  The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma. , 2013, Mutation research.

[21]  Shridar Ganesan,et al.  Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. , 2013, Cancer discovery.

[22]  Lodewyk F. A. Wessels,et al.  A regression model for estimating DNA copy number applied to capture sequencing data , 2012, Bioinform..

[23]  A. D’Andrea,et al.  Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. , 2012, Genes & development.

[24]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[25]  John L Hopper,et al.  Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Fiona A. Stewart,et al.  Strategies to improve radiotherapy with targeted drugs , 2011, Nature Reviews Cancer.

[27]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[28]  T. Helleday.  Homologous recombination in cancer development, treatment and development of drug resistance. , 2010, Carcinogenesis.

[29]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[30]  Bernard Asselain,et al.  Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature , 2010, Breast Cancer Research and Treatment.

[31]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[33]  P. Borst,et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.

[34]  P. Rosenberg,et al.  Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry , 2008, Haematologica.

[35]  M. Ljungman,et al.  Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines. , 2007, Cancer letters.

[36]  R. Phillips,et al.  Tailoring targeted therapy to individual patients: lessons to be learnt from the development of mitomycin C. , 2007, Cancer genomics & proteomics.

[37]  Bhuvanesh Singh,et al.  Downregulation of Fanconi Anemia Genes in Sporadic Head and Neck Squamous Cell Carcinoma , 2007, ORL.

[38]  C. Waes,et al.  Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines. , 2007, Cancer letters.

[39]  T. Watts,et al.  Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers and the risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium , 2007, BDJ.

[40]  Alan Ashworth,et al.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.

[41]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Brose,et al.  Genome‐Wide Profiling of Oral Squamous Cell Carcinoma by Array‐Based Comparative Genomic Hybridization , 2006, The Laryngoscope.

[43]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[44]  P. J. Brooks,et al.  DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesis. , 2005, Alcohol.

[45]  Mei Liu,et al.  Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival , 2004, Oncogene.

[46]  A. Sartorelli,et al.  Bioactivation and resistance to mitomycin C. , 2004, Methods in enzymology.

[47]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[48]  Xiang Guo,et al.  Head and neck cancers. , 2003, Cancer chemotherapy and biological response modifiers.

[49]  J. Shah,et al.  High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. , 2003, Archives of otolaryngology--head & neck surgery.

[50]  A. D’Andrea,et al.  The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. , 2001, Molecular genetics and metabolism.

[51]  S. Ganesan,et al.  Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. , 2001, Molecular cell.

[52]  C. Mathew,et al.  Spectrum of mutations in the Fanconi anaemia group G gene, FANCG/XRCC9 , 2000, European Journal of Human Genetics.

[53]  P. Pharoah,et al.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases , 2000, British Journal of Cancer.

[54]  C. Mathew,et al.  Complementation analysis in Fanconi anemia: assignment of the reference FA-H patient to group A. , 2000, American journal of human genetics.

[55]  F. Kikkawa,et al.  Transfection of human cytochrome P-450 reductase cDNA and its effect on the sensitivity to toxins. , 1996, Oncology.

[56]  S. Rockwell,et al.  Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[57]  M. Tomasz,et al.  Mitomycin C: small, fast and deadly (but very selective). , 1995, Chemistry & biology.

[58]  D. Brachman,et al.  Molecular biology of head and neck cancer. , 1994, Seminars in oncology.

[59]  C. la Vecchia,et al.  A comparison of the joint effects of alcohol and smoking on the risk of cancer across sites in the upper aerodigestive tract. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[60]  M. Sasaki,et al.  A high susceptibility of Fanconi's anemia to chromosome breakage by DNA cross-linking agents. , 1973, Cancer research.